114 related articles for article (PubMed ID: 34565620)
1. Corrigendum to 'GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft' [Canc. Lett. 330 (2013) 22-32].
Fu J; Rodova M; Roy SK; Sharma J; Singh KP; Srivastava RK; Shankar S
Cancer Lett; 2021 Dec; 522():282. PubMed ID: 34565620
[No Abstract] [Full Text] [Related]
2. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells.
Shultz LD; Lyons BL; Burzenski LM; Gott B; Chen X; Chaleff S; Kotb M; Gillies SD; King M; Mangada J; Greiner DL; Handgretinger R
J Immunol; 2005 May; 174(10):6477-89. PubMed ID: 15879151
[TBL] [Abstract][Full Text] [Related]
3. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells.
Ito M; Hiramatsu H; Kobayashi K; Suzue K; Kawahata M; Hioki K; Ueyama Y; Koyanagi Y; Sugamura K; Tsuji K; Heike T; Nakahata T
Blood; 2002 Nov; 100(9):3175-82. PubMed ID: 12384415
[TBL] [Abstract][Full Text] [Related]
4. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice.
Ishikawa F; Yasukawa M; Lyons B; Yoshida S; Miyamoto T; Yoshimoto G; Watanabe T; Akashi K; Shultz LD; Harada M
Blood; 2005 Sep; 106(5):1565-73. PubMed ID: 15920010
[TBL] [Abstract][Full Text] [Related]
5. Corrigendum to "Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer" [Canc. Lett. 438 (2018, Dec 1) 165-173].
Lin CC; Lo MC; Moody R; Jiang H; Harouaka R; Stevers N; Tinsley S; Gasparyan M; Wicha M; Sun D
Cancer Lett; 2020 Jun; 480():51. PubMed ID: 32229161
[No Abstract] [Full Text] [Related]
6. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81].
Fu Z; Chen C; Zhou Q; Wang Y; Zhao Y; Zhao X; Li W; Zheng S; Ye H; Wang L; He Z; Lin Q; Li Z; Chen R
Cancer Lett; 2022 Oct; 545():215836. PubMed ID: 35934602
[No Abstract] [Full Text] [Related]
7. Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling" [Canc. Lett. 471 (2020) 135-146].
Yue Y; Qian W; Li J; Wu S; Zhang M; Wu Z; Ma Q; Wang Z
Cancer Lett; 2022 Nov; 549():215913. PubMed ID: 36152564
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215].
Zhang B; Ye H; Ren X; Zheng S; Zhou Q; Chen C; Lin Q; Li G; Wei L; Fu Z; Zhang Y; Hu C; Li Z; Chen R
Cancer Lett; 2022 Nov; 548():215897. PubMed ID: 36050250
[No Abstract] [Full Text] [Related]
9. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice.
Ito R; Katano I; Kawai K; Hirata H; Ogura T; Kamisako T; Eto T; Ito M
Transplantation; 2009 Jun; 87(11):1654-8. PubMed ID: 19502956
[TBL] [Abstract][Full Text] [Related]
10. An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/beta2-microglobulin(null) mice.
Ishikawa F; Livingston AG; Wingard JR; Nishikawa Si; Ogawa M
Exp Hematol; 2002 May; 30(5):488-94. PubMed ID: 12031656
[TBL] [Abstract][Full Text] [Related]
11. Corrigendum to "MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer", [Canc. Lett. 399 (2017) 53-63].
Ou C; Sun Z; Li X; Li X; Ren W; Qin Z; Zhang X; Yuan W; Wang J; Yu W; Zhang S; Peng Q; Yan Q; Xiong W; Li G; Ma J
Cancer Lett; 2018 Apr; 420():260. PubMed ID: 29429755
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-κB pathway" [Canc. Lett. 342 (2014) 150-158].
Zhao Z; Wu MS; Zou C; Tang Q; Lu J; Liu D; Wu Y; Yin J; Xie X; Shen J; Kang T; Wang J
Cancer Lett; 2021 Dec; 522():281. PubMed ID: 34561145
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells" [Canc. Lett. 412 (2018) 297-307].
Le HT; Nguyen HT; Min HY; Hyun SY; Kwon S; Lee Y; Le THV; Lee J; Park JH; Lee HY
Cancer Lett; 2018 Jun; 424():136. PubMed ID: 29573834
[No Abstract] [Full Text] [Related]
14. beta2 microglobulin-deficient (B2m(null)) NOD/SCID mice are excellent recipients for studying human stem cell function.
Kollet O; Peled A; Byk T; Ben-Hur H; Greiner D; Shultz L; Lapidot T
Blood; 2000 May; 95(10):3102-5. PubMed ID: 10807775
[TBL] [Abstract][Full Text] [Related]
15. Long-term engraftment and expansion of tumor-derived memory T cells following the implantation of non-disrupted pieces of human lung tumor into NOD-scid IL2Rgamma(null) mice.
Simpson-Abelson MR; Sonnenberg GF; Takita H; Yokota SJ; Conway TF; Kelleher RJ; Shultz LD; Barcos M; Bankert RB
J Immunol; 2008 May; 180(10):7009-18. PubMed ID: 18453623
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "Targeting autophagy in cancer stem cells as an anticancer therapy" [Canc. Lett. 393 (2017) 33-39].
Lei Y; Zhang D; Yu J; Dong H; Zhang J; Yang S
Cancer Lett; 2018 Mar; 416():149. PubMed ID: 29307478
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Long noncoding RNA LINC00657 inhibits cervical cancer development by sponging miR-20a-5p and targeting RUNX3" [Canc. Lett. 498 (2021) 130-141].
Qin X; Zhou M; Lv H; Mao X; Li X; Guo H; Li L; Xing H
Cancer Lett; 2021 Jun; 508():73-75. PubMed ID: 33798906
[No Abstract] [Full Text] [Related]
18. Intrathymic injection of hematopoietic progenitor cells establishes functional T cell development in a mouse model of severe combined immunodeficiency.
Tuckett AZ; Thornton RH; O'Reilly RJ; van den Brink MRM; Zakrzewski JL
J Hematol Oncol; 2017 May; 10(1):109. PubMed ID: 28511686
[TBL] [Abstract][Full Text] [Related]
19. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene.
King M; Pearson T; Shultz LD; Leif J; Bottino R; Trucco M; Atkinson MA; Wasserfall C; Herold KC; Woodland RT; Schmidt MR; Woda BA; Thompson MJ; Rossini AA; Greiner DL
Clin Immunol; 2008 Mar; 126(3):303-14. PubMed ID: 18096436
[TBL] [Abstract][Full Text] [Related]
20. Corrigendum to "cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells" [Canc. Lett. 403 (2017) 260-270].
Fu H; He Y; Qi L; Chen L; Luo Y; Chen L; Li Y; Zhang N; Guo H
Cancer Lett; 2021 Feb; 498():240-241. PubMed ID: 33221059
[No Abstract] [Full Text] [Related]
[Next] [New Search]
